Trading information on Kenvue Inc., a consumer-health business spun off from Johnson & Johnson, is displayed on a screen during the company’s IPO at the New York Stock Exchange in New York City, May 4, 2023.
Brendan Mcdermid | Reuters
Kimberly-Clark said on Monday it will acquire Tylenol-maker Kenvue in a deal valued at about $48.7 billion.
This story is developing. Please check back for updates.
About The Author
